233 related articles for article (PubMed ID: 26829221)
21. A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.
Ziegler DS; Keating J; Kesari S; Fast EM; Zawel L; Ramakrishna N; Barnes J; Kieran MW; Veldhuijzen van Zanten SE; Kung AL
Neuro Oncol; 2011 Aug; 13(8):820-9. PubMed ID: 21724651
[TBL] [Abstract][Full Text] [Related]
22. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
23. Glioma-associated endothelial cells are chemoresistant to temozolomide.
Virrey JJ; Golden EB; Sivakumar W; Wang W; Pen L; Schönthal AH; Hofman FM; Chen TC
J Neurooncol; 2009 Oct; 95(1):13-22. PubMed ID: 19381445
[TBL] [Abstract][Full Text] [Related]
24. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
Minea RO; Duc TC; Swenson SD; Cho HY; Huang M; Hartman H; Hofman FM; Schönthal AH; Chen TC
PLoS One; 2020; 15(9):e0238238. PubMed ID: 32881880
[TBL] [Abstract][Full Text] [Related]
25. NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas.
Cho HY; Wang W; Jhaveri N; Lee DJ; Sharma N; Dubeau L; Schönthal AH; Hofman FM; Chen TC
Mol Cancer Ther; 2014 Aug; 13(8):2004-17. PubMed ID: 24994771
[TBL] [Abstract][Full Text] [Related]
26. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
[TBL] [Abstract][Full Text] [Related]
27. Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.
Candolfi M; Yagiz K; Wibowo M; Ahlzadeh GE; Puntel M; Ghiasi H; Kamran N; Paran C; Lowenstein PR; Castro MG
Clin Cancer Res; 2014 Mar; 20(6):1555-1565. PubMed ID: 24501391
[TBL] [Abstract][Full Text] [Related]
28. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
D'Alessandro G; Grimaldi A; Chece G; Porzia A; Esposito V; Santoro A; Salvati M; Mainiero F; Ragozzino D; Di Angelantonio S; Wulff H; Catalano M; Limatola C
Oncotarget; 2016 May; 7(21):30781-96. PubMed ID: 27096953
[TBL] [Abstract][Full Text] [Related]
29. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Momota H; Nerio E; Holland EC
Cancer Res; 2005 Aug; 65(16):7429-35. PubMed ID: 16103096
[TBL] [Abstract][Full Text] [Related]
30. Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection.
Akbar U; Jones T; Winestone J; Michael M; Shukla A; Sun Y; Duntsch C
J Neurooncol; 2009 Sep; 94(2):203-12. PubMed ID: 19337695
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of a polypyridyl chelating ligand: in vitro and in vivo inhibition of glioma.
David CN; Frias ES; Elix CC; McGovern KE; Walker AM; Eichler JF; Wilson EH
ASN Neuro; 2015; 7(1):. PubMed ID: 25732707
[TBL] [Abstract][Full Text] [Related]
32. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
Kim JT; Kim JS; Ko KW; Kong DS; Kang CM; Kim MH; Son MJ; Song HS; Shin HJ; Lee DS; Eoh W; Nam DH
Oncol Rep; 2006 Jul; 16(1):33-9. PubMed ID: 16786120
[TBL] [Abstract][Full Text] [Related]
33. Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Zhang YH; Yue ZJ; Zhang H; Tang GS; Wang Y; Liu JM
Eur J Pharm Biopharm; 2010 Nov; 76(3):371-5. PubMed ID: 20816959
[TBL] [Abstract][Full Text] [Related]
34. A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.
Chen X; Tai L; Gao J; Qian J; Zhang M; Li B; Xie C; Lu L; Lu W; Lu W
J Control Release; 2015 Nov; 218():29-35. PubMed ID: 26428461
[TBL] [Abstract][Full Text] [Related]
35. The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts.
Adhikari B; Li J; Brandel MG; Futalan D; Akers J; Deming T; Chen CC; Carter BS
J Clin Neurosci; 2017 Nov; 45():288-292. PubMed ID: 28867360
[TBL] [Abstract][Full Text] [Related]
36. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
37. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Karachi A; Yang C; Dastmalchi F; Sayour EJ; Huang J; Azari H; Long Y; Flores C; Mitchell DA; Rahman M
Neuro Oncol; 2019 Jun; 21(6):730-741. PubMed ID: 30668768
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
39. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
40. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
Kim TG; Kim CH; Park JS; Park SD; Kim CK; Chung DS; Hong YK
Clin Vaccine Immunol; 2010 Jan; 17(1):143-53. PubMed ID: 19889936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]